Biotech Healthcare secures EU MDR certification for ophthalmic and medical devices

Ophthalmology Times Europe· July 14, 2026

Biotech Healthcare has officially received EU Medical Device Regulation (MDR) certification for its range of ophthalmic and medical devices. This regulatory milestone confirms that the company's products meet the stringent safety and performance standards required for the European market. For the healthcare and biotech sector, this certification ensures continued access to critical ophthalmic technologies and reinforces the importance of regulatory compliance in maintaining market presence.

Read the full story at Ophthalmology Times Europe

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to Ophthalmology Times Europe.

More in Healthcare & Biotech

Lonza Group Stock Reflects Steady Outlook Amid Global Healthcare Demand

Lonza Group, a leading Swiss contract development and manufacturing organization (CDMO), is positioning itself as a critical partner for global pharmaceutical and nutrition companies amid rising demand for complex therapies. As drug makers increasingly outsource capital-intensive manufacturing to focus on research and development, Lonza’s role in the global supply chain has become a key indicator for the health of the biotech sector. This shift toward specialized outsourcing supports a long-term growth thesis for the company, particularly as advanced modalities like cell and gene therapies move through clinical pipelines.

July 12, 2026

GC Genome Launches 'Naite' Telomere Test, and More

GC Genome has introduced the 'Naite' test, a diagnostic tool designed to measure biological age and aging rates by analyzing telomere length. This development coincides with several major advancements in the Korean healthcare sector, including Seoul National University Hospital's move toward clinical trials for a new CAR-T therapy and Macrogen’s large-scale genetic identification project for the Ministry of National Defense. These initiatives reflect a growing trend in the biotech industry toward personalized diagnostics, advanced immunotherapy, and the application of genomic data for public service and specialized hospital care.

July 11, 2026

Amgen Stock Reflects Biotech Heavyweight's Steady Role in US Healthcare

Amgen Inc. remains a cornerstone of the U.S. biotechnology sector, leveraging a diversified portfolio of biologic and biosimilar therapies to maintain its status as a large-cap industry leader. The company focuses on high-need medical areas including oncology and inflammatory conditions, utilizing its extensive manufacturing infrastructure to support global product launches. As a staple in major equity benchmarks, Amgen’s financial stability and consistent revenue streams provide a unique profile that balances mature product performance with ongoing clinical pipeline development.

July 11, 2026

Stocks in Focus today: Supriya Lifescience; Rubicon Research; Fortis Healthcare; Fermenta Biotech

Supriya Lifescience, Rubicon Research, Fortis Healthcare, and Fermenta Biotech have been identified as key stocks to watch within the healthcare and biotech sectors for the current trading session. These companies represent a diverse cross-section of the industry, including active pharmaceutical ingredient manufacturing, specialized research and development, and hospital services. Their inclusion in the focus list indicates significant market interest that could impact the broader healthcare investment landscape.

July 6, 2026